Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.70%
#2 Ontology Gas Ontology Gas +17.76%
#3 GoPlus Security GoPlus Security +9.80%
#4 Janction Janction +9.64%
#5 DMT-NAT DMT-NAT +7.80%
#6 Provenance Blockchain Provenance Blockchain +6.63%
#7 B3 (Base) B3 (Base) +6.09%
#8 Ontology Ontology +6.08%
#9 Status Status +5.87%
#10 Everything Everything +5.64%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
設定
言語
日本
通貨
USD
テーマ
PJSC Pharmsynthez PJSC Pharmsynthez

PJSC Pharmsynthez

LIFE
株式のランク #34086
PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation,... PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation, production, and supply of both proprietary (officinal) and generic active pharmaceutical ingredients across Russia and the Commonwealth of Independent States (CIS). Its portfolio of branded medicines includes Neovir, Segidrin, Fenasid, and Penkrofton, which are employed in critical therapeutic areas such as oncology, gynecology, the management of immune deficiencies, and tuberculosis. Public Joint-Stock Company Pharmsynthez has also established a collaboration with HiFiBiO Therapeutics Inks for the clinical advancement and market introduction of their SARS-CoV-2 neutralizing antibody within Russia. The company, which began operations in 1996, is headquartered in St. Petersburg, Russia.
株価
$0.02082992
最終同期: 2026-08-14
時価総額
$6.27M
変化（1日）
-3.31%
変化（1年）
-51.62%
国
RU
取引 PJSC Pharmsynthez (LIFE)

カテゴリー

Healthcare
PJSC Pharmsynthez（LIFE）の収益
Aug 2026 時点の収益 TTM: 0
PJSC Pharmsynthez の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
PJSC Pharmsynthez の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE